泰凌医药(01011)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01011 泰凌医药

休市中 07-10 14:43:54

0.420

+0.005

+1.20%

最高0.420	最低0.390	成交量37.00万
今开0.400	昨收0.415	日振幅7.23%
总市值3.99亿	流通市值3.99亿	总股本9.49亿
成交额14.81万	换手率0.04%	流通股本9.49亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01011","market":"HK","secType":"STK","nameCN":"泰凌医药","latestPrice":0.42,"timestamp":1783665834844,"preClose":0.415,"halted":0,"volume":370000,"delay":0,"changeRate":0.012048192771084348,"floatShares":949000000,"shares":949000000,"eps":-0.048803089297053216,"marketStatus":"休市中","change":0.005,"latestTime":"07-10 14:43:54","open":0.4,"high":0.42,"low":0.39,"amount":148100,"amplitude":0.072289,"askPrice":0.43,"askSize":20000,"bidPrice":0.395,"bidSize":40000,"shortable":0,"etf":0,"ttmEps":-0.03468591989840314,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783906200000},"marketStatusCode":7,"adr":0,"listingDate":1303228800000,"exchange":"SEHK","adjPreClose":0.415,"openAndCloseTimeList":[[1783647000000,1783656000000],[1783659600000,1783670400000]],"volumeRatio":10.109289609200035,"lotSize":10000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01011/wiki","defaultTab":"wiki","newsList":[{"id":"1152815747","title":"泰凌医药(01011)延迟寄发涉贷款资本化认购事项通函至7月31日","url":"https://stock-news.laohu8.com/highlight/detail?id=1152815747","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152815747?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:41","pubTimestamp":1783672878,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团有限公司（01011，下称“泰凌医药”）7月10日发布公告称，公司原计划在6月17日公告日起15个营业日内（即2026年7月10日或之前）寄发有关根据特别授权以贷款资本化方式认购股份的通函。因需额外时间准备并落实通函内若干资料，公司预计通函寄发时间将延迟至2026年7月31日或之前。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194001111","title":"泰凌医药（01011）拟聘中正天恒为新核数师 审计费约88万元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1194001111","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194001111?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:42","pubTimestamp":1783420958,"startTime":"0","endTime":"0","summary":"2026年7月7日，泰凌医药公告称，董事会已按香港联交所《上市规则》第13.51条作出决议，拟委任中正天恒会计师有限公司为公司及其附属公司的新核数师，以填补大华马施雲会计师事务所有限公司于2026年6月4日股东周年大会后退任所致的临时空缺。上述委任须待公司股东于即将召开的股东特别大会通过普通决议案后方可生效，新核数师任期将至公司下一届股东周年大会结束为止。1) 中正天恒提出的审计费用；","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649098132","title":"泰凌医药(01011)议决委任中正天恒为新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2649098132","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649098132?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:38","pubTimestamp":1783420702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布公告，经考虑本公司审核委员会(审核委员会)的推荐建议，董事会已议决委任中正天恒会计师有限公司(中正天恒)为本公司新核数师，以填补大华马施云退任后的临时空缺，自股东于股东特别大会(定义见下文)上批准之日起生效，且其任期将直至本公司下一届股东退年大会结束为止。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170751155","title":"泰凌医药宣布张博志辞任首席执行官，安迪·景杰接棒","url":"https://stock-news.laohu8.com/highlight/detail?id=1170751155","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170751155?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:53","pubTimestamp":1783414401,"startTime":"0","endTime":"0","summary":"2026年7月3日，泰凌医药发布公告，宣布公司首席执行官张博志已辞去职务，该决定自2026年7月3日起生效。同日，公司董事会任命安迪·景杰为新任首席执行官，接替张博志的工作，任命亦于同日生效。\n此次管理层变动标志着泰凌医药进入新的发展阶段。张博志的离任原因未在公告中详细说明。新任首席执行官安迪·景杰将肩负起领导公司未来战略规划与日常运营的重任。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128893808","title":"中国泰凌医药集团董事会于2026年7月3日批准通过正式举报政策","url":"https://stock-news.laohu8.com/highlight/detail?id=1128893808","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128893808?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:35","pubTimestamp":1783089316,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团董事会于2026年7月3日正式批准并通过了一项公司内部举报政策。此举标志着该公司在完善治理结构、强化内部监督机制方面迈出了重要一步。该政策的建立旨在为员工及利益相关方提供一个安全、保密的渠道，以报告任何可能违反法律法规、公司规章制度或职业道德准则的行为。通过设立明确的举报流程与保护措施，公司期望能够及时发现并处理潜在风险，进一步维护企业诚信与合规运营，保障股东权益及公司的长远健康发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648661986","title":"泰凌医药(01011)：吴静杰获委任为行政总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2648661986","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648661986?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:23","pubTimestamp":1783088598,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布公告，张伯之先生辞任行政总裁职务，以投入更多时间于其个人及其他事务，自2026年7月3日起生效。张伯之先生辞任后不再担任本公司及其任何附属公司的任何职务。吴静杰先生已获委任为本公司行政总裁，自2026年7月3日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168289584","title":"泰凌医药6月股份变动月报：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1168289584","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168289584?lang=zh_cn&edition=full","pubTime":"2026-07-03 19:39","pubTimestamp":1783078747,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团有限公司于2026年7月3日发布截至2026年6月30日止的月度证券变动报告。报告显示，公司当月在普通股和优先股的注册股本及已发行股份、库存股数方面均无变动，股本保持稳定。月报显示，6月期间并未发生新增发行、购回或注销股份等活动，亦无股份期权或其他股权激励变动。公司确认其已符合香港联交所证券上市规则相关的公众持股量要求，并已遵守相关适用的法律法规。公告由执行董事吴铁签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644747632","title":"泰凌医药(01011)拟推进贷款资本化 折让约20.65%发行合共8.476亿股抵销债务","url":"https://stock-news.laohu8.com/highlight/detail?id=2644747632","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644747632?lang=zh_cn&edition=full","pubTime":"2026-06-17 23:01","pubTimestamp":1781708486,"startTime":"0","endTime":"0","summary":"于本公告日期，杨氏集团于公司已发行股本中拥有约21.23%权益。根据相关认购协议，第二名认购人将认购合共2.508亿股认购股份。贷款资本化完成后，假设完成于2025年12月31日作实，集团于2025年12月31日的债务总额将由约人民币4.49亿元减至人民币1.82亿元。此外，该等债务的利息将仅计算至认购协议日期止且不再进一步计息，而贷款资本化将全额抵销该等债务。清偿该等债务将对集团有利，尤其是由于集团截至2025年12月31日止年度取得亏损人民币2630万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642259548","title":"泰凌医药2025年报被出具“不发表意见”后 续聘大华决议遭96.62%高票否决 AI医疗故事尚未贡献一分钱收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2642259548","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642259548?lang=zh_cn&edition=full","pubTime":"2026-06-12 11:01","pubTimestamp":1781233260,"startTime":"0","endTime":"0","summary":"2026年6月4日，港股泰凌医药召开股东周年大会，一项看似常规的“重新委任核数师”的决议案引发轩然大波。最终投票结果显示，关于重新委任大华马施云会计师事务所有限公司为公司核数师的第3项普通决议案，赞成票仅为7，253，850股，反对票高达207，054，239股，以大比例被否决。这是泰凌医药近年最激烈的一次“以票否决”式治理事件。　　大华马施云会计师事务所有限公司已自股东周年大会结束时起退任公司核数师。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-06-12/doc-iniccfxx0342889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CHAT","BK1191","01011","159891","ARTY","AGIX","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640155149","title":"泰凌医药(01011)：大华马施云退任核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155149","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640155149?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:20","pubTimestamp":1780564807,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布公告，由于有关重新委任大华马施云会计师事务所有限公司为公司核数师之第3项决议案未获股东周年大会通过，大华马施云会计师事务所有限公司已退任公司核数师，自股东周年大会结束时起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122435541","title":"泰凌医药2026年5月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1122435541","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122435541?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:35","pubTimestamp":1780306552,"startTime":"0","endTime":"0","summary":"泰凌医药于2026年6月1日发布了截至2026年5月31日的股份变动月报。公告显示，公司普通股注册股数为62,592,500,000股，每股面值0.0000008美元，注册股本约为USD 50,074；优先股注册股数为32,500,000股，每股面值0.0000008美元，注册股本约为USD 26。截至5月底，公司股本总额约USD 50,100，普通股已发行股份为948,997,694股，与上月保持一致。当月内公司未发生新增发行、购回或注销等股份变动，也无任何其它股份或股权激励计划的增减事宜，整体股本保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639286036","title":"泰凌医药(01011)拟出售于泰凌海外的部分或全部股权权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2639286036","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639286036?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:40","pubTimestamp":1780044034,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药 发布公告，内容有关北京康辰药业股份有限公司主动提出对北京康辰生物科技有限公司的资产进行拆分，解散联营关系。为缓解集团流动性紧张，及战略转型的需要，公司拟出售其于泰凌医药(海外)控股有限公司的部分或全部股权权益。泰凌海外为公司的间接全资附属公司，并透过其直接全资附属公司泰凌医药(亚洲)有限公司间接持有北京康辰生物科技有限公司的25.30%股权权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143359787","title":"泰凌医药2026年4月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1143359787","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143359787?lang=zh_cn&edition=full","pubTime":"2026-05-11 11:26","pubTimestamp":1778469981,"startTime":"0","endTime":"0","summary":"2026年5月11日，泰凌医药发布截至2026年4月30日止的证券变动月报表。公告显示，公司普通股法定/注册股本数为62,592,500,000股，面值USD 0.0000008，合计USD 50,074；优先股为32,500,000股，面值USD 0.0000008，合计USD 26。截至报告期末，两类股份的法定/注册股本合计USD 50,100，较上月无变动。公告同时披露，公司期末已发行但未被公司持有且作为发行在外的普通股股票数量为948,997,694股，持平于上月，期内未发生股份新增发行、购回及注销。本次公告由执行董事吴铁签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116920554","title":"泰凌医药（NT Pharma）自揭历史关联交易违规　股份质押与贷款协议已全部终止并清偿","url":"https://stock-news.laohu8.com/highlight/detail?id=1116920554","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116920554?lang=zh_cn&edition=full","pubTime":"2026-05-08 22:21","pubTimestamp":1778250119,"startTime":"0","endTime":"0","summary":"泰凌医药集团公告称，董事会近日发现并披露多项于2019年至2024年间与关连人士进行而未按《上市规则》及时公告的交易，主要涉及两笔股份质押及三份贷款协议。根据最新披露，这些交易分别触及《上市规则》第14章及第14A章有关非常重大出售事项及不获豁免关连交易的规定。2024年7月，NT Pharma 进一步将其在NT Pharma 的股权质押予Annie Investment。2025年7月双方签订终止协议，相关质押已解除，股权已恢复原状。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633517457","title":"泰凌医药(01011)：郭芝聪获委任为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2633517457","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633517457?lang=zh_cn&edition=full","pubTime":"2026-05-08 22:21","pubTimestamp":1778250099,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布公告，郭芝聪先生(郭先生)已获委任为独立非执行董事及本公司审核委员会(审核委员会)主席，自2026年5月8日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162852893","title":"泰凌医药2025年度业绩：收入降幅显著、亏损显著收窄，持续推进AI医疗与传统业务融合","url":"https://stock-news.laohu8.com/highlight/detail?id=1162852893","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162852893?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:27","pubTimestamp":1777544840,"startTime":"0","endTime":"0","summary":"截至2025年12月31日止年度，泰凌医药录得收益约人民币2,416万元，服务成本约人民币1,455万元，同比降幅更为明显，使毛利升至约人民币961万元，同比增长82.7%。年内亏损则由上年度的约人民币5,348万元缩减至约人民币2,626万元，幅度收窄近五成。审计报告显示，鉴于亏损与净负债规模较大，集团的持续经营能力存在不确定性。总体而言，泰凌医药于2025年度收入虽有明显回落，但亏损幅度显著收窄，并在智慧健康与AI融合方向上加大布局力度。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"泰凌医药2025年度业绩：收入降幅显著、亏损显著收窄，持续推进AI医疗与传统业务融合","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165069040","title":"泰凌医药授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1165069040","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165069040?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:26","pubTimestamp":1777544806,"startTime":"0","endTime":"0","summary":"泰凌医药公告显示，公司获股东大会提案授权，拟回购不超过截至决议通过当日已发行股本总数10%的股份。根据公告，公司当前已发行股本为948,997,694股，此次购回上限约为94,899,769股。公告附带近12个月的股份交易价格，最高价约为1.35港元，最低价约为0.22港元。公司方面强调，将综合考虑财务状况及市场情况审慎行使回购授权。根据董事会意见，回购计划仍需在2026年6月4日召开的股东周年大会上正式审议和表决，并在授权期限内按实际情况执行。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"泰凌医药授予董事股份购回授权，规模达已发行股本一成","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627314434","title":"泰凌医药(01011)：楼勇斌获委任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2627314434","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627314434?lang=zh_cn&edition=full","pubTime":"2026-04-13 18:31","pubTimestamp":1776076291,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布公告，楼勇斌先生已获委任为公司非执行董事，自2026年4月13日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427817.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143006625","title":"泰凌医药3月新增发行约2.75亿股 普通股总数增至约9.49亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1143006625","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143006625?lang=zh_cn&edition=full","pubTime":"2026-04-02 15:47","pubTimestamp":1775116040,"startTime":"0","endTime":"0","summary":"泰凌医药于2026年4月2日发布截至2026年3月31日的股份变动月报表。报告期内，公司普通股由原先的674,246,015股增加至948,997,694股，增幅为274,751,679股。该增发所涉普通股以每股港币0.45的价格发行，于2026年3月25日完成。公司注册股本方面，普通股注册股份数为62,592,500,000股，优先股注册股份数为32,500,000股，本报告期未发生变化，公司注册股本总额维持在美元50,100。截至本月末，公司普通股总数由此增至948,997,694股，且公司确认已符合香港联交所相应的公众持股量要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624053500","title":"泰凌医药(01011)发布年度业绩，股东应占亏损2604.1万元 同比减少51.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624053500","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624053500?lang=zh_cn&edition=full","pubTime":"2026-04-01 00:05","pubTimestamp":1774973136,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布截至2025年12月31日止年度业绩，该集团取得收益2415.8万元，同比减少36.36%;公司拥有人应占亏损2604.1万元，同比减少51.2%;每股亏损4.22分。公告称，本集团的传统业务于回顾年度内继续缩减，而医疗科技相关业务于2025年仍处于资产准备及合规整合阶段，尚未形成收入贡献。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ntpharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.087},{"period":"3month","weight":-0.3913},{"period":"6month","weight":-0.5059},{"period":"1year","weight":-0.087},{"period":"ytd","weight":-0.4878}],"compareEarnings":[{"period":"1week","weight":0.0353},{"period":"1month","weight":-0.0095},{"period":"3month","weight":-0.0664},{"period":"6month","weight":-0.0784},{"period":"1year","weight":0.0061},{"period":"ytd","weight":-0.0568}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国泰凌医药集团有限公司是一家主要提供医药产品销售及分销服务的投资控股公司。该公司通过两个分部运营业务。数字服务分部主要提供与骨健康知识的市场推广及宣传有关的数字服务。销售代理分部主要提供代理服务为代理客户向外部客户销售医疗及健康相关产品服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.003177},{"month":2,"riseRate":0.466667,"avgChangeRate":0.045108},{"month":3,"riseRate":0.4,"avgChangeRate":-0.034671},{"month":4,"riseRate":0.6,"avgChangeRate":0.215361},{"month":5,"riseRate":0.3125,"avgChangeRate":-0.031879},{"month":6,"riseRate":0.3125,"avgChangeRate":-0.023905},{"month":7,"riseRate":0.375,"avgChangeRate":-0.010922},{"month":8,"riseRate":0.266667,"avgChangeRate":-0.075011},{"month":9,"riseRate":0.4,"avgChangeRate":0.038353},{"month":10,"riseRate":0.4,"avgChangeRate":-0.009707},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.071764},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.020063}],"exchange":"SEHK","name":"泰凌医药","nameEN":"NT PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰凌医药(01011)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰凌医药(01011)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰凌医药,01011,泰凌医药股票,泰凌医药股票老虎,泰凌医药股票老虎国际,泰凌医药行情,泰凌医药股票行情,泰凌医药股价,泰凌医药股市,泰凌医药股票价格,泰凌医药股票交易,泰凌医药股票购买,泰凌医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰凌医药(01011)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰凌医药(01011)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}